narazaciclib + letrozole

Narazaciclib + letrozole is an investigational oral combination therapy under clinical study for recurrent metastatic low-grade endometrioid endometrial cancer (LGEEC). Narazaciclib is a novel, orally available multi-kinase inhibitor that targets CDK 4, CDK 6, and additional kinases relevant to cell proliferation, motility, and survival. Letrozole is a nonsteroidal aromatase inhibitor that reduces estrogen production, thereby depriving hormone-dependent tumors of critical growth signals. This combination is intended as a second- or third-line option and is being evaluated for synergistic efficacy, leveraging narazaciclib's ability to inhibit cell cycle progression through CDK 4/6 blockade and letrozole's hormonal suppression to slow cancer growth. Both are administered orally on a continuous dosing schedule in ongoing Phase 1/2a trials[1][3][5][7].

Other names

narazaciclib + letrozole